SCG Cell Therapy's SCG101V Receives Approval for Clinical Trial in China for Hepatitis B Treatment SCG Cell Therapy has achieved a significant milestone with its investigational drug SCG101V, approved for clinical trials in China, targeting chronic hepatitis B.

SCG Cell Therapy's SCG101V Receives Approval for Clinical Trial in China for Hepatitis B Treatment #Singapore #SCG101 #SCG_Cell_Therapy #Hepatitis_B

SCG Cell Therapy Unveils Groundbreaking Clinical Data for SCG101 in Hepatocellular Carcinoma Treatment SCG Cell Therapy introduces significant clinical findings on SCG101, a novel TCR T cell therapy for HBV-related hepatocellular carcinoma (HCC) at EASL Congress 2025.

SCG Cell Therapy Unveils Groundbreaking Clinical Data for SCG101 in Hepatocellular Carcinoma Treatment #Singapore #SCG101 #SCG_Cell_Therapy #HBV_Treatment

SCG Cell Therapy's SCG101 Shows Promise in Hepatitis B Cancer Therapy at AASLD 2024 SCG Cell Therapy presents encouraging Phase 1 results for SCG101, a novel TCR-T therapy targeting HBV-related liver cancer at AASLD 2024. Learn more about its potential.

SCG Cell Therapy's SCG101 Shows Promise in Hepatitis B Cancer Therapy at AASLD 2024 #Singapore #SCG101 #SCG_Cell_Therapy #TCR-T_Therapy